- Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024 - - Ended year with US$337.1 million in cash, cash equivalents and short-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results